Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

Utilizing IP Street, you can search within technology classes to identify firms and patents anchored within a scope of inventions. Whether you are looking for inbound or outbound licensing opportunities, our search tools can help you Discover, Measure, Compare, Connect to, better business opportunities.

What is a normal royalty fee? How are fees generally determined? How can we grasp which patent portfolios are the best bang for the buck? With IP Street, you can demystify the complex which enables you to identify both inbound- and outbound- licensing strategies.

"At the heart of any successful organization there is the recognition that only through the firm's talent will it acheive its objectives. With that in mind, the talent management organization's role is to align its strategy for acquiring, managing and developing talent to the business' strategic objectives. Business leaders want to assist with this goal. According to the Aberdeen Group, the top priority in 2011 for best-in-class companies is aligning their business and talent strategy." (Facteau and Hall, July 2011, talent management TM). Let the patent search tools at IPstreet.com help you identify key assets.

Ask yourself? Which side of the game do you want to be on? Do you want to be remembered as the executive who failed to recognize the business opportunity staring you in the face? Or do you want to be remembered as the visionary who executed and altered your company forever? The choice is yours.